AI Virtanen Institute Department of Biotechnology and Molecular Medicine, University of Eastern Finland/Kuopio, Finland.
J Invertebr Pathol. 2011 Jul;107 Suppl:S106-12. doi: 10.1016/j.jip.2011.05.010.
Baculoviruses have proven capacity for the production of recombinant proteins including virus-like particles and as viral vectors. Recent progress in preclinical studies suggest that baculoviruses have potential as new vectors for gene therapy but so far no clinical trials have been performed. To date, no specific guidelines for the use of baculoviruses as human gene therapy vectors exist but researchers can utilize existing guidelines made for other biological products. Because of the long history of research on baculoviruses, a lot of knowledge has been obtained that forms a good basis for the gene therapy development process. This article gives an overview of the current status of the application of baculovirus vectors in gene therapy and summarizes some of the challenges to overcome before the first clinical trials with baculoviruses can be accomplished.
杆状病毒已被证明有能力生产重组蛋白，包括病毒样颗粒和病毒载体。最近的临床前研究进展表明，杆状病毒具有作为基因治疗新载体的潜力，但迄今为止尚未进行临床试验。迄今为止，尚无将杆状病毒用作人类基因治疗载体的具体指南，但研究人员可以利用为其他生物制品制定的现有指南。由于对杆状病毒的研究历史悠久，已经获得了很多知识，为基因治疗的发展过程奠定了良好的基础。本文概述了杆状病毒载体在基因治疗中的应用现状，并总结了在进行杆状病毒首次临床试验之前需要克服的一些挑战。
